Stock Track | Absci Corporation Plunges 9.71% Following Disappointing Q3 Results and Revenue Miss

Stock Track11-13

Absci Corporation (NASDAQ: ABSI) saw its stock price plummet 9.71% on Wednesday following the release of its third-quarter 2025 financial results, which fell significantly short of analyst expectations. The biotechnology company, specializing in AI-powered drug discovery, reported disappointing figures that triggered a sell-off among investors.

For the third quarter, Absci reported revenue of $378,000, representing a steep 77.78% decrease compared to the same period last year and falling far below the analyst consensus estimate of $1.52 million. The company's earnings per share (EPS) came in at $(0.20), slightly better than the expected $(0.21), but still indicating substantial losses. Absci's net loss for the quarter widened to $28.7 million, while operating expenses remained high at $30.5 million.

Despite the challenging financial results, Absci reported some positive developments in its drug pipeline. The company announced interim Phase 1 results for ABS-101 and plans to initiate a Phase 1/2a trial for ABS-201 in December. Additionally, Absci is expanding its strategy for ABS-201 to include endometriosis, with a Phase 2 trial anticipated to begin in the fourth quarter of 2026. However, these advancements were not enough to offset investor concerns about the company's declining revenue and expanding losses, leading to the significant stock price decline.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1135959188?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 09:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135959188","market":"sg","top_or_hot":-1,"title":"Stock Track | Absci Corporation Plunges 9.71% Following Disappointing Q3 Results and Revenue Miss","media":"Stock Track","content":"<p>Absci Corporation (NASDAQ: ABSI) saw its stock price plummet 9.71% on Wednesday following the release of its third-quarter 2025 financial results, which fell significantly short of analyst expectations. The biotechnology company, specializing in AI-powered drug discovery, reported disappointing figures that triggered a sell-off among investors.</p>\n\n<p>For the third quarter, Absci reported revenue of $378,000, representing a steep 77.78% decrease compared to the same period last year and falling far below the analyst consensus estimate of $1.52 million. The company's earnings per share (EPS) came in at $(0.20), slightly better than the expected $(0.21), but still indicating substantial losses. Absci's net loss for the quarter widened to $28.7 million, while operating expenses remained high at $30.5 million.</p>\n\n<p>Despite the challenging financial results, Absci reported some positive developments in its drug pipeline. The company announced interim Phase 1 results for ABS-101 and plans to initiate a Phase 1/2a trial for ABS-201 in December. Additionally, Absci is expanding its strategy for ABS-201 to include endometriosis, with a Phase 2 trial anticipated to begin in the fourth quarter of 2026. However, these advancements were not enough to offset investor concerns about the company's declining revenue and expanding losses, leading to the significant stock price decline.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Absci Corporation Plunges 9.71% Following Disappointing Q3 Results and Revenue Miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Absci Corporation Plunges 9.71% Following Disappointing Q3 Results and Revenue Miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-13 09:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Absci Corporation (NASDAQ: ABSI) saw its stock price plummet 9.71% on Wednesday following the release of its third-quarter 2025 financial results, which fell significantly short of analyst expectations. The biotechnology company, specializing in AI-powered drug discovery, reported disappointing figures that triggered a sell-off among investors.</p>\n\n<p>For the third quarter, Absci reported revenue of $378,000, representing a steep 77.78% decrease compared to the same period last year and falling far below the analyst consensus estimate of $1.52 million. The company's earnings per share (EPS) came in at $(0.20), slightly better than the expected $(0.21), but still indicating substantial losses. Absci's net loss for the quarter widened to $28.7 million, while operating expenses remained high at $30.5 million.</p>\n\n<p>Despite the challenging financial results, Absci reported some positive developments in its drug pipeline. The company announced interim Phase 1 results for ABS-101 and plans to initiate a Phase 1/2a trial for ABS-201 in December. Additionally, Absci is expanding its strategy for ABS-201 to include endometriosis, with a Phase 2 trial anticipated to begin in the fourth quarter of 2026. However, these advancements were not enough to offset investor concerns about the company's declining revenue and expanding losses, leading to the significant stock price decline.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABSI","symbol_name":"Absci Corporation.","start_time":0,"source_url":"","article_id":"1135959188","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135959188","pubTimestamp":1762995816,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Absci Corporation (NASDAQ: ABSI) saw its stock price plummet 9.71% on Wednesday following the release of its third-quarter 2025 financial results, which fell significantly short of analyst...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABSI":"Absci Corporation."},"translate_title":"个股追踪|Absci Corporation因令人失望的第三季度业绩和营收未达预期暴跌9.71%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABSI":1},"content_text":"Absci Corporation (NASDAQ: ABSI) saw its stock price plummet 9.71% on Wednesday following the release of its third-quarter 2025 financial results, which fell significantly short of analyst expectations. The biotechnology company, specializing in AI-powered drug discovery, reported disappointing figures that triggered a sell-off among investors.\nFor the third quarter, Absci reported revenue of $378,000, representing a steep 77.78% decrease compared to the same period last year and falling far below the analyst consensus estimate of $1.52 million. The company's earnings per share (EPS) came in at $(0.20), slightly better than the expected $(0.21), but still indicating substantial losses. Absci's net loss for the quarter widened to $28.7 million, while operating expenses remained high at $30.5 million.\nDespite the challenging financial results, Absci reported some positive developments in its drug pipeline. The company announced interim Phase 1 results for ABS-101 and plans to initiate a Phase 1/2a trial for ABS-201 in December. Additionally, Absci is expanding its strategy for ABS-201 to include endometriosis, with a Phase 2 trial anticipated to begin in the fourth quarter of 2026. However, these advancements were not enough to offset investor concerns about the company's declining revenue and expanding losses, leading to the significant stock price decline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1135959188","isCrawlerRequest":true}